Abstract 170P
Background
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare primary hepatic malignancy considered to be a variant of hepatocellular carcinoma. It accounts for about ≈ 1-5% of all HCCs .Surgery (resection/liver transplantation) is the current standard treatment and remains the only potentially curative treatment option ; however, the role of chemotherapy is still controversial . Therefore, we conducted this study to evaluate the efficacy of chemotherapy in improving the survival of patients with Fibrolamellar hepatocellular carcinoma (FL-HCC).
Methods
Using SEER database, we extracted the data of 100 patients with FL-HCC from 2004 to 2014. There were 40 (40%) patients underwent surgery combined with chemotherapy, while 60(60%) of them received chemotherapy only. Patients’ demographics and staging system were assessed.
Results
Patients with FL-HCC had better outcomes when they received surgery alone compared to those who received surgery combined with chemotherapy, where overall 1-year relative survival rates were 98.3% and 95%, respectively (significant p value of 0.031).Subgroup analysis revealed that there is a highly significant P-value (< 0.0001) regarding both different age groups and staging system. On the other hand ;there is No significance for the p value was reported to the race or sex.Table:
170P
Variables | Survival of Patients | p value | |
---|---|---|---|
surgery combined with chemotherapy | Surgery alone | ||
Sex Male Female | 92.3% 100% | 100% 95.7% | 0.246 |
Age 0-19 20-39 40-59 60-79 | 100% 84.6% 100% 100%** | 100% 100% 100% 81.8% | <0.0001*** |
Race White Black Asian or Pacific Islander | 96.7% 100%** 85.7% | 98% 100% * | 0.838 |
staging I II IIIA IIIB IIIC IV | 100% 100%** 100% 100%** 100% 85.7% | 96.4% 100% 100% 100%** 100% 100% | <0.0001*** |
Highly significant P-value < 0.0001.
**few patients reported.
*NO recorded patients.
Conclusions
surgery alone without chemotherapy in patients with FL-HCC shows higher 1-year relative survival rates when compared to surgery combined with chemotherapy. So, we recommend surgery alone without chemotherapy as a superior modality for better survival. Further studies should be conducted on a larger number of patients to confirm the results. Keywords: Fibrolamellar hepatocellular carcinoma (FL-HCC), chemotherapy, surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yasmine Ashraf Mohamed Ali.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
437P - Correlation between bio-impedance analysis and abdominal CT scan to diagnose decreased muscle mass in adult cancer patients
Presenter: Andree Kurniawan
Session: Poster display session
Resources:
Abstract
438P - Evaluating mitochondrial biomarkers between fatigue subclasses identified using latent class analysis in early-stage breast cancer patients
Presenter: Yi Long Toh
Session: Poster display session
Resources:
Abstract
440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
441P - A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
442P - Relationship between QOL and support elderly patients with permanent colostomies
Presenter: Yukiko Orii
Session: Poster display session
Resources:
Abstract
443P - The effectiveness of individual nutritional counselling for patients with advanced cancer undergoing chemotherapy: A preliminary study
Presenter: Saori Koshimoto
Session: Poster display session
Resources:
Abstract
444P - The prophylactic effect of 0.1% fluorometholone eye drops on eye disorders caused by high-dose cytarabine
Presenter: Takayuki Tsuchiya
Session: Poster display session
Resources:
Abstract
445P - Safety and feasibility of extending flushing interval every 3 months for maintenance of TICVPS in CRC patients after completion of curative intended treatments
Presenter: Sang Bo Oh
Session: Poster display session
Resources:
Abstract
446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy
Presenter: Jada Harika
Session: Poster display session
Resources:
Abstract
447P - Hypomagnesaemia: An unnoticed problem in lung cancer patients treated with concurrent chemoradiation
Presenter: Sharif Ahmed
Session: Poster display session
Resources:
Abstract